Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $7.50 Consensus Price Target from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have received an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $7.50.

Several equities analysts have commented on SANA shares. Wedbush started coverage on shares of Sana Biotechnology in a report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 price objective on the stock. Morgan Stanley began coverage on shares of Sana Biotechnology in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Sana Biotechnology in a research note on Tuesday, June 24th.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $3.97 on Tuesday. Sana Biotechnology has a one year low of $1.26 and a one year high of $7.30. The company has a market cap of $944.11 million, a P/E ratio of -3.75 and a beta of 1.91. The firm’s fifty day moving average price is $3.45 and its two-hundred day moving average price is $2.78.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. As a group, equities research analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of large investors have recently bought and sold shares of SANA. Marex Group plc acquired a new stake in Sana Biotechnology during the second quarter worth about $10,423,000. Corient Private Wealth LLC grew its stake in Sana Biotechnology by 264.7% during the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock worth $3,101,000 after buying an additional 824,505 shares in the last quarter. AQR Capital Management LLC grew its stake in Sana Biotechnology by 136.7% during the second quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company’s stock worth $3,703,000 after buying an additional 783,217 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Sana Biotechnology during the second quarter worth about $1,916,000. Finally, Millennium Management LLC grew its stake in Sana Biotechnology by 604.8% during the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company’s stock worth $1,188,000 after buying an additional 625,481 shares in the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.